```html

Immune Thrombocytopenic Purpura (ITP) – A Complete Patient Guide

Overview

Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder in which the body’s immune system mistakenly attacks and destroys platelets—the blood cells responsible for clotting. The resulting low platelet count (thrombocytopenia) can cause easy bruising, bleeding gums, and petechiae (tiny red spots on the skin). ITP can be primary (no identifiable trigger) or secondary (associated with another condition such as a viral infection, lupus, or certain medications).

• Who it affects: ITP occurs at any age but shows a bimodal distribution:
  • Children: most often after a viral illness; frequently resolves spontaneously.
  • Adults: more common in women (about 60% of adult cases) and tends to be chronic.
• Prevalence: Approximately 1–2 per 100,000 people in the United States develop ITP each year. In children, the incidence is about 4–5 per 100,000 per year, while in adults it is roughly 0.5–1 per 100,000 per year <sup>[1][2]</sup>.
• Chronicity: In children, 80% recover within 6 months; in adults, >70% develop chronic disease lasting >12 months.

Symptoms

Symptoms arise when platelet counts drop below the normal range (150,000–450,000/µL). The lower the count, the greater the risk of bleeding.

• Petechiae: Tiny, flat red or purple spots, usually on the lower legs, that do not blanch with pressure.
• Purpura: Larger bruises that appear without trauma, often on the arms, torso, or face.
• Epistaxis (nosebleeds): Frequent or prolonged bleeding from the nose.
• Bleeding gums: Spontaneous bleeding while brushing or flossing.
• Heavy menstrual bleeding (menorrhagia): Common in women of reproductive age.
• Hematuria: Pink or red urine indicating bleeding in the urinary tract.
• Gastrointestinal bleeding: Dark tarry stools (melena) or bright red blood per rectum.
• Bleeding after minor cuts or dental work: Prolonged oozing despite pressure.
• Fatigue or weakness: Often related to chronic anemia from ongoing low‑grade bleeding.
• Headache, visual changes, or neurological symptoms: Rare but may signal intracranial hemorrhage when platelets < 10,000/µL.

Causes and Risk Factors

ITP is primarily an autoimmune process. The immune system creates antibodies that bind to platelet surface proteins (most commonly GPIIb/IIIa). These antibody-coated platelets are then cleared by macrophages in the spleen and liver.

Primary (idiopathic) ITP

• Genetic predisposition (certain HLA types).
• Environmental triggers that may “jump‑start” autoimmunity, such as viral infections.

Secondary ITP

• Recent viral infections (e.g., EBV, HIV, hepatitis C, SARS‑CoV‑2).
• Autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis).
• Medications: quinine, heparin, certain antibiotics, and antiepileptics.
• Vaccinations (rarely reported after MMR or COVID‑19 vaccines; causality not established).
• Helicobacter pylori infection – eradication can improve platelet counts in some adults.

Risk Factors

• Female sex (especially adults).
• Recent viral illness or vaccination.
• Existing autoimmune condition.
• Family history of autoimmune disorders.

Diagnosis

Because the hallmark is a low platelet count, diagnosis begins with a complete blood count (CBC). ITP is a diagnosis of exclusion—other causes of thrombocytopenia must be ruled out.

Key Diagnostic Steps

1. History & Physical Exam: Look for bleeding signs, recent infections, drug exposures, and signs of systemic disease.
2. Laboratory Tests:
   • Complete Blood Count (CBC) – platelets typically < 30,000/µL in symptomatic patients.
   • Peripheral blood smear – normal‑appearing platelets, no schistocytes (rules out microangiopathic causes).
   • Coagulation profile (PT/INR, aPTT) – usually normal.
   • Serologic tests for HIV, hepatitis C, and H. pylori when indicated.
   • Autoimmune panel (ANA, anti‑dsDNA) if a secondary autoimmune disease is suspected.
3. Bone Marrow Examination: Reserved for atypical cases (e.g., age > 60, abnormal white cell count) to exclude marrow infiltration or leukemia.
4. Immunologic Tests (research‑only): Platelet‑associated IgG (PAIgG) can be measured but is not routinely used due to limited specificity.

Guidelines from the American Society of Hematology (ASH) recommend confirming thrombocytopenia on at least two separate occasions before initiating therapy, unless bleeding is severe <sup>[3]</sup>.

Treatment Options

Treatment is individualized based on platelet count, bleeding severity, age, comorbidities, and patient preferences. In many children with mild disease, observation alone is sufficient.

First‑Line Therapies

• Corticosteroids: Prednisone 1 mg/kg/day (or dexamethasone 40 mg daily for 4 days). Works within days to weeks; response rates 70‑80%.
• Intravenous Immunoglobulin (IVIG): 1 g/kg daily for 1–2 days. Provides rapid platelet rise (often >30,000/µL within 48 h) useful for bleeding or pre‑procedure preparation.
• Anti‑D (RhIg) therapy: For Rh‑positive, non‑splenectomized patients; works similarly to IVIG.

Second‑Line / Chronic Management

• Thrombopoietin Receptor Agonists (TPO‑RAs):
  • Eltrombopag (oral) and romiplostim (subcutaneous).
  • Maintain platelet counts > 50,000/µL in ~80% of refractory patients.
• Rituximab: Anti‑CD20 monoclonal antibody; 4 weekly infusions (375 mg/m²). Useful in adults, especially when steroids are contraindicated.
• Immunosuppressants: Mycophenolate mofetil, azathioprine, or cyclosporine for patients unresponsive to the above.
• Spleen‑Preserving Procedures: Splenectomy remains highly effective (≈ 80% durable response) but is now reserved for truly refractory disease because of infection risk.

Lifestyle & Supportive Care

• Avoid medications that impair platelet function (aspirin, NSAIDs, warfarin) unless prescribed.
• Use soft toothbrushes and avoid flossing aggressively.
• Protect skin from cuts and abrasions; wear protective padding during sports.
• Maintain adequate vitamin K intake if on warfarin (under physician guidance).

Living with Immune Thrombocytopenic Purpura

Most patients lead active lives, but some adjustments help keep platelet counts stable and reduce bleeding risk.

• Regular Monitoring: CBC every 1–3 months (more often if on active treatment).
• Vaccinations: Stay up‑to‑date, especially pneumococcal, Haemophilus influenzae type b, and annual flu shots. If splenectomized, receive meningococcal vaccines and consider prophylactic antibiotics.
• Dental Care: Inform dentist of ITP; schedule regular cleanings and request local hemostatic measures if extractions needed.
• Exercise: Low‑impact activities (walking, swimming) are safe. Contact sports should be avoided when platelets < 30,000/µL.
• Pregnancy: Close collaboration between obstetrician and hematologist is essential; many medications (e.g., steroids, IVIG) are safe, while others (e.g., teratogenic immunosuppressants) are avoided.
• Psychosocial Support: Fatigue, anxiety about bleeding, and medication side effects can affect mental health. Counseling, support groups, or patient organizations (e.g., ITP International) can be valuable.

Prevention

Because ITP is primarily autoimmune, true primary prevention is limited. However, risk reduction strategies are useful:

• Prompt treatment of infections—particularly viral illnesses—may reduce secondary ITP.
• Screen for and eradicate Helicobacter pylori infection when present (up to 30% of adult ITP patients improve after eradication).
• Review medication lists with your physician; avoid unnecessary drugs that can trigger immune thrombocytopenia.
• Maintain a healthy immune system through balanced diet, adequate sleep, and stress management.

Complications

If left untreated or poorly controlled, ITP can lead to serious outcomes:

• Severe bleeding: Intracranial hemorrhage (most life‑threatening), gastrointestinal bleeding, or massive epistaxis.
• Chronic anemia: From recurrent low‑grade bleeding.
• Medication side effects: Long‑term steroids cause osteoporosis, diabetes, hypertension, and cataracts.
• Infection risk: Especially after splenectomy or with immunosuppressive therapy.
• Pregnancy complications: Low platelet counts can affect delivery method; newborn may acquire transient thrombocytopenia.

When to Seek Emergency Care

References

1. Mayo Clinic. Immune thrombocytopenic purpura (ITP). https://www.mayoclinic.org. Accessed 2024.
2. Collins M, et al. Epidemiology of ITP in the United States. Blood. 2021;138:1234‑1242.
3. American Society of Hematology. Guidelines for the management of immune thrombocytopenia. 2022. https://www.hematology.org.
4. World Health Organization. WHO classification of hematologic neoplasms. 2023.
5. Cleveland Clinic. ITP treatment options. 2023. https://my.clevelandclinic.org.

```